Here are six drugmakers' financial results for the first quarter of fiscal year 2017.
AbbVie
Humira, the company's best-selling arthritis drug, produced sales of $4.12 billion in the first quarter, representing more than 60 percent of AbbVie's total quarterly revenue. The drugmaker's net revenue jumped 9.7 percent to $6.54 billion for the first quarter.
Amgen
Amgen reported total revenue of $5.5 billion in fiscal year 2017, down 1 percent from the same period the year prior. Sales of its arthritis drug, Enbrel, and cancer drug, Neupogen, fell 15 percent and 31 percent, respectively, compared to the same quarter a year prior.
AstraZeneca
AstraZeneca posted revenue of $5.4 billion, marking a 12 percent drop year over year. The drugmaker attributed the revenue decrease to declining sales of its cholesterol drug Crestor, which saw sales fall 45 percent from the same quarter a year prior.
Bristol-Myers Squibb Co.
Bristol-Myers' first quarter revenue in fiscal year 2017 increased 12 percent to $4.93 billion, largely driven by sales of cancer drugs Opdivo and Yervoy, and the blood thinner Eliquis. Quarterly sales for Opdivo, Yervoy and Eliquis jumped 60 percent, 25 percent and 50 percent, respectively.
Eli Lilly and Co.
The drugmaker posted higher than expected quarterly adjusted profit due to more demand for its newer drugs, such as the diabetes treatment Trulicity and the psoriasis treatment Taltz. Eli Lilly's revenue increased 7 percent from the same quarter a year prior to $5.23 billion for the first quarter of fiscal year 2017.
Novartis
Novartis' revenue decreased 1 percent from the same quarter a year prior to $11.5 million. The drugmaker's plaque psoriasis drug Cosentyx hit sales of $410 million for the quarter, marking a 133 percent increase from the first quarter of fiscal year 2016.
More articles on supply chain:
3 things to know about National Prescription Drug Take Back Day
Pharmacist lobby group: PBMs prioritize profits over medication affordability
GHX recognizes 2017 healthcare supply chain leaders